ABCL vs LIVN
AbCellera Biologics Inc. vs LivaNova — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
67
Buy
VS
| Metric | ABCL | LIVN |
|---|
| AI Score |
67
|
70
|
| Price |
$11.38
|
$82.25
|
| P/E Ratio |
-21.07×
|
23.83×
|
| ROE |
-15.1%
|
-20.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
68.2%
|
| Debt / Equity |
0.15×
|
0.27×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
93.5
|
60.6
|
| Beta |
1.191
|
0.872
|
| Expected Upside |
—
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus LIVN.
LIVN leads by 3 points.
LIVN scores 70/100 (Buy) versus ABCL at 67/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 93 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
LIVN Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- ROE of 15.4% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Risk/reward is unfavorable: 5.6% downside vs 0.8% upside.